Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Jakob Dupont is Director at Bolt Biotherapeutics. OQRO lists 9 transactions filed with the SEC under this name, the latest on Jun 12, 2026, each linked to the official Form 4.
Director
Disclosures on record
9
Companies involved
1
Bolt BiotherapeuticsBOLT
9 disclosures · Dec 2025 – Jun 2026
Jun 10, 20265,000disclosed Jun 12
DetailsOfficial recordDec 12, 20251,000disclosed Dec 17
DetailsOfficial recordDec 12, 2025849disclosed Dec 17
DetailsOfficial recordDec 12, 20251,100disclosed Dec 17
DetailsOfficial recordDec 12, 20252,500disclosed Dec 17
DetailsOfficial recordDec 12, 20251,100disclosed Dec 17
DetailsOfficial recordDec 12, 20252,500disclosed Dec 17
DetailsOfficial recordDec 12, 2025849disclosed Dec 17
DetailsOfficial recordDec 12, 20251,000disclosed Dec 17
DetailsOfficial recordJakob Dupont has no open-market purchase on record since 2019 across 2 companies. Sales in 4 of the 8 years since 2019.
Jakob Dupont reported 0 open-market purchases and 15 sales since 2019; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2023 | — | $18K1×1 trade |
| 2022 | — | $243K7×7 trades |
| 2021 | — | $312K5×5 trades |
| 2019 | — | $632K2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Jakob Dupont has no open-market purchase on record since 2019 across 2 companies. Sales in 4 of the 8 years since 2019.
In SEC filings since 2019: no open-market purchase is on record; the latest open-market sale is from 2023.
2 companies: Atara Biotherapeutics (ATRA, 2021–2023), Gossamer Bio (GOSS, 2019).
Jakob Dupont reported 0 open-market purchases and 13 sales here, 2021 to 2023.
Jakob Dupont reported 0 open-market purchases and 2 sales here, 2019.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
